WebAug 27, 2024 · Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stelara ® (ustekinumab), in the United States (US). WebMay 2, 2024 · Bio-Thera Solutions, Ltd. and Hikma Pharmaceuticals PLC announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stelara®, in the United States. Hikma resumes launch of generic Advair Diskus® 4/20/2024
Biogen’s RoActemra Biosimilar Begins EU Approvals Process
Web1 day ago · GUANGZHOU, China--(BUSINESS WIRE)--#AACR--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced the company will present one poster concerning Phase 1 clinical results for BAT1006 at the 2024 American Association for Cancer Research ("AACR") Annual Meeting taking place April 14 - April 19, … WebAug 27, 2024 · Hikma told Generics Bulletin earlier this year it was reevaluating the US biosimilars market after witnessing successful launches from several of its rivals. Now … britannic bold download free
Hikma, Bio-Thera enter exclusive agreement for monoclonal …
WebAug 30, 2024 · Bio-Thera Solutions Bert E. Thomas IV +1 410 627 1734 (mobile) Senior Vice President, Business Development [email protected] Hikma Pharmaceuticals PLC Susan Ringdal +44 (0)20 7399 2760/ +44 7776 477050 EVP, Strategic Planning and Global Affairs [email protected] Steve Weiss +1 732 720 2830/ +1 732 788 8279 … WebAug 27, 2024 · Bio-Thera Solutions has found a partner to help with US distribution of its proposed ustekinumab biosimilar, which entered phase 3 trial development this summer. … WebBio-Thera is eligible for an upfront payment of $20 million as well as further development and commercial milestones of up to $130 million. "Partnering with Hikma to commercialize BAT2206, our ustekinumab biosimilar, further validates the high quality of the work performed at Bio-Thera," said Dr. Shengfeng Li, CEO of Bio-Thera Solutions. britannic blueprints